Don’t miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!® Get the Fresh, Nutrient Rich, Piping Hot Picks Everyday! Sign-up, its FREE!
Hemispherx Biopharma, HEB, is a specialty pharmaceutical company, engages in the clinical development of new drug therapies based on natural immune system.
http://www.dailystockdeals.com/topten/hot-biotechnology-stocks-idra-04-01-2013
Source: company, OxBridge Research, Daily Stock Deals
CAMBRIDGE, Mass.–(BUSINESS WIRE)–
Idera Pharmaceuticals, Inc. (IDRA) today announced that it has completed dosing in its Phase 1 trial of IMO-8400 in healthy subjects. In addition, the Company announced that its protocol for a Phase 2 study of IMO-8400 in patients with psoriasis has received “no objection” clearance from the Competent Authority of the Netherlands. IMO-8400 is an antagonist of Toll-like receptors (TLRs) 7, 8 and 9, and is in clinical development for the treatment of autoimmune diseases.
During the first quarter of 2013, the Company completed the escalating single-dose portion of the Phase 1 trial of IMO-8400 and has now completed patient dosing in the multiple-dose portion of the trial. The multiple-dose portion of the trial involved two dose levels of IMO-8400, 0.3 and 0.6 mg/kg, and placebo, with six subjects receiving each treatment of four weekly doses. The Company expects to report top-line data from the multiple-dose portion of the trial later in the second quarter of 2013.
Source: company, OxBridge Research, Daily Stock Deals
HEB, Hemispherx Biopharma
Hemispherx Biopharma, HEB, is a specialty pharmaceutical company, engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Its products include Ampligen, an experimental drug under clinical development for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Hepatitis B, human immunodeficiency virus (HIV), renal cell carcinoma, and malignant melanoma; Alferon N Injection, an injectable formulation of natural alpha interferon for the treatment of certain categories of genital warts; and Alferon LDO, an experimental low-dose oral liquid formulation of natural alpha interferon for the treatment of influenza and other emerging viral diseases.
Don’t miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!® Get the Fresh, Nutrient Rich, Piping Hot Picks Everyday! Sign-up, its FREE!
Source: company, OxBridge Research, Daily Stock Deals
Fourth quarter revenue totaled $8.9 million, up $6.7 million from the 2011 period, resulting primarily from the partnering transactions. For the full year, Progenics reported revenues of $14.0 million, compared to $84.8 million for 2011, a decrease primarily from 2011 recognition of the Salix collaboration.
Royalty income for the quarter was $0.8 million compared to $1.3 million in the fourth quarter of 2011, reflecting stocking activity in 2011. Royalty income for the year was $5.0 million compared to $3.0 million for 2011.
Net sales reported to Progenics by Salix (in millions):
| Three Months Ended | Year Ended | ||||
| December 31, | September 30, | December 31, | |||
| 2012 | 2011 | 2012 | 2012 | 2011 | |
| U.S. | $4.1 | $8.0 | $3.8 | $29.2 | $21.5 |
| Ex-U.S. | 1.1 | 0.8 | 1.1 | 4.0 | 5.5 |
| Global | $5.2 | $8.8 | $4.9 | $33.2 | $27.0 |
Fourth Quarter Highlights
Recent Events
Idera Pharmaceuticals (IDRA)
Financial Results
As of December 31, 2012, cash and cash equivalents totaled $10.1 million compared to $24.6 million at December 31, 2011.
Fourth Quarter Results
Net loss applicable to common stockholders for the three months ended December 31, 2012 was $6.5 million, or $0.24 per diluted share, compared to net loss applicable to common stockholders of $9.7 million, or $0.35 per diluted share, for the same period in 2011. There was no significant revenue recognized in the fourth quarter of 2012 or 2011. Research and development expenses for the three months ended December 31, 2012 totaled $3.1 million compared to $5.7 million for the same period in 2011. General and administrative expenses for the three months ended December 31, 2012, totaled $1.3 million compared to $1.5 million for the same period in 2011.
Full Year Results
Net loss applicable to common stockholders for the year ended December 31, 2012 was $22.5 million, or $0.81 per diluted share, compared to net loss applicable to common stockholders of $28.3 million, or $1.03 per diluted share, for 2011. Total revenues in each of the years ended December 31, 2012 and 2011 were $0.1 million. Research and development expenses for the year ended December 31, 2012 totaled $13.7 million compared to $18.0 million for 2011. General and administrative expenses for the year ended December 31, 2012 totaled $6.3 million compared to $7.9 million for 2011.
Source: the company, OxBridge Research Daily Stock Deals
High Octane Solar and Alternative Energy stocks! Top 10 Picks
Fiscal Cliff brought much needed sunshine to Solar Stocks. Renewable energy stocks across the board got a huge boost from the extension of credits and R&D expenditure. You could have doubled your money in a matter of weeks, see our Solar picks.
Stay ahead, stay informed sign-up and make money, its FREE
Today’s Top Picks
SONS, CIS, ZLCS, IDRA, BGMD, CSUN, CYTK, QUIK, CRDC, CSIQ
Don’t miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®
we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.